文献速递糖尿病

检查点抑制剂相关自身免疫性糖尿病以C肽丢失和胰腺萎缩为特征

Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

该多中心病例系列纳入36例检查点抑制剂相关自身免疫性糖尿病(CIADM)患者,中位诊断时间为ICI启动后15周,69%以糖尿病酮症酸中毒起病,1个月内100%患者C肽降低;17例患者胰腺体积测量显示从治疗前至CIADM诊断后6个月平均下降41%。

要点

  • CIADM诊断时69%患者发生糖尿病酮症酸中毒,1个月内全部患者C肽降低。
  • 传统1型糖尿病自身抗体在CIADM患者中仅43%阳性。
  • 胰腺体积从ICI治疗前至CIADM诊断后6个月平均下降41%。

核心结论

  • CIADM发病过程中出现显著的生化与影像学变化,C肽快速丢失是可用于辅助诊断的独特特征,因自身抗体常为阴性。

研究设计与样本

  • 多中心病例系列,回顾电子病历连续识别36例CIADM患者,诊断标准为既往ICI治疗、新发高血糖(血糖≥11.1 mmol/L和/或糖化血红蛋白≥6.5%)、起病1个月内胰岛素缺乏(C肽<0.4 nmol/L或糖尿病酮症酸中毒)。
  • 对17例CIADM患者及3组对照(7例ICI相关胰腺炎、13例无症状ICI相关脂肪酶升高、11例ICI治疗对照)使用计算机断层扫描体积测量法测量胰腺体积。

主要发现

  • 所有患者均接受抗程序性细胞死亡蛋白1或抗程序性细胞死亡配体1治疗,从ICI启动至CIADM诊断的中位时间为15周。
  • 起病时25例(69%)发生糖尿病酮症酸中毒,27例(84%)C肽降低,至1个月时100%患者C肽降低。
  • 传统1型糖尿病自身抗体在15/35例(43%)中阳性,起病时13/27例(48%)脂肪酶升高。
  • 4例有纵向脂肪酶检测的患者中,脂肪酶升高峰值出现在CIADM诊断前1个月。
  • CIADM患者ICI治疗前胰腺体积低于对照,从治疗前至CIADM诊断后6个月平均下降41%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To conduct a multicenter case series characterizing the clinical characteristics at presentation and pancreatic volume changes of patients with checkpoint inhibitor-associated autoimmune diabetes (CIADM). RESEARCH DESIGN AND METHODS: Electronic medical records were reviewed with 36 consecutive patients identified with CIADM, as defined by (1) previous immune checkpoint inhibitor (ICI) therapy, (2) new-onset hyperglycemia (blood glucose level ≥ 11.1 mmol/L and/or glycosylated hemoglobin ≥ 6.5%), and (3) insulin deficiency [C-peptide <0.4 nmol/L or diabetic ketoacidosis (DKA)] within 1 month of presentation. Pancreatic volume was available and measured using computed tomography volumetry for 17 patients with CIADM and 3 sets of control patients: 7 with ICI-related pancreatitis, 13 with asymptomatic ICI-related lipase elevation, and 11 ICI-treated controls for comparison. RESULTS: All patients had either anti-programmed cell death protein 1 or anti-programmed cell death ligand 1 therapy. Median time from ICI commencement to CIADM diagnosis was 15 weeks. At presentation, 25 (69%) had DKA, 27 (84%) had low C-peptide, and, by 1 month, 100% had low C-peptide. Traditional type 1 diabetes autoantibodies were positive in 15/35 (43%). Lipase was elevated in 13/27 (48%) at presentation. In 4 patients with longitudinal lipase testing, elevated levels peaked 1 month prior to CIADM diagnosis. Pancreatic volume was lower pre-ICI in CIADM patients compared with controls and demonstrated a mean decline of 41% from pretreatment to 6 months post-CIADM diagnosis. CONCLUSION: Pronounced biochemical and radiologic changes occur during CIADM pathogenesis. Rapid loss of C-peptide is a distinct characteristic that can be used to aid diagnosis as autoantibodies are often negative.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wu L, Carlino MS, Brown DA, et al. Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy. J Clin Endocrinol Metab. 2024. PMID: 37997380. doi:10.1210/clinem/dgad685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。